WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/032899    International Application No.:    PCT/KR2008/006116
Publication Date: 25.03.2010 International Filing Date: 16.10.2008
C07K 16/18 (2006.01)
Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY [KR/KR]; 111 Gwahangno Yuseong-gu Daejeon 305-806 (KR) (For All Designated States Except US).
PARK, Young Woo [KR/KR]; (KR) (For US Only).
HOE, Kwang-Lae [KR/KR]; (KR) (For US Only).
CHOI, So-Young [KR/KR]; (KR) (For US Only).
PARK, Ji Hyun [KR/KR]; (KR) (For US Only).
SONG, Eun-Jung [KR/KR]; (KR) (For US Only).
YU, Jung [KR/KR]; (KR) (For US Only).
SOHN, Myung-Ho [KR/KR]; (KR) (For US Only).
KIM, Sungsub [KR/KR]; (KR) (For US Only).
JANG, Myeoung Hee [KR/KR]; (KR) (For US Only).
KIM, Dong-Jin [KR/KR]; (KR) (For US Only)
Inventors: PARK, Young Woo; (KR).
HOE, Kwang-Lae; (KR).
CHOI, So-Young; (KR).
PARK, Ji Hyun; (KR).
SONG, Eun-Jung; (KR).
YU, Jung; (KR).
SOHN, Myung-Ho; (KR).
KIM, Sungsub; (KR).
JANG, Myeoung Hee; (KR).
KIM, Dong-Jin; (KR)
Agent: LEE, Won-Hee; 8th floor, Sung-ji Heights II, 642-16 Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR)
Priority Data:
10-2008-0092736 22.09.2008 KR
Abstract: front page image
(EN)The present invention relates to an alpha-endolase (ENO1) -specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to ENO1. The ENO1-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.
(FR)La présente invention concerne un anticorps humain spécifique de l'alpha-endolase (ENO1), et plus particulièrement un anticorps humain comprenant une région déterminant la complémentarité (CDR) et une région de charpente (FR) dérivé d'un anticorps humain lié spécifiquement à ENO1. L'anticorps humain ENO1-spécifique exprimé dans les différents types de cellules cancéreuses de la présente invention peut être utilisé dans le diagnostic du cancer, la classification de la maladie, la visualisation, le traitement et l'évaluation pronostique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: Korean (KO)